Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hervé Tilly

Showing results (1-10 of 254) with videos related to

Pageof 26
Sort By:
La Revue Du Praticien|March 13, 2010
[Treatment options in non-Hodgkin lymphomas]Hervé Tilly
La Revue Du Praticien|June 18, 2002
[Differential diagnosis of lymphomas]Hervé Tilly
Medecine Sciences : M/S|October 6, 2004
[Clinical application of gene-expression profiling in lymphome]Fabrice Jardin, Hervé Tilly
Future Oncology (London, England)|September 21, 2020
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphomaVincent Camus, Hervé Tilly
Leukemia & Lymphoma|October 15, 2008
Treatment of follicular lymphoma: current statusHervé Tilly, Andrew Zelenetz
Leukemia & Lymphoma|February 17, 2012
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone: until what age?Fabrice Jardin, Hervé Tilly
Leukemia & Lymphoma|October 15, 2008
Epidemiology, pathology and treatment of non-follicular indolent lymphomasOla Landgren, Hervé Tilly
Expert Review of Hematology|October 30, 2016
Managing early failures with R-CHOP in patients with diffuse large B-cell lymphomaVincent Camus, Hervé Tilly
The Lancet. Oncology|February 2, 2008
Dose dance in lymphomasBertrand Coiffier, Hervé Tilly
The Lancet. Healthy Longevity|September 14, 2022
Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?Fabrice Jardin, Hervé Tilly
Pageof 26

Showing results (1-10 of 254) with videos related to

Sort By:
Pageof 26
La Revue Du Praticien|March 13, 2010
[Treatment options in non-Hodgkin lymphomas]Hervé Tilly
La Revue Du Praticien|June 18, 2002
[Differential diagnosis of lymphomas]Hervé Tilly
Medecine Sciences : M/S|October 6, 2004
[Clinical application of gene-expression profiling in lymphome]Fabrice Jardin, Hervé Tilly
Future Oncology (London, England)|September 21, 2020
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphomaVincent Camus, Hervé Tilly
Leukemia & Lymphoma|October 15, 2008
Treatment of follicular lymphoma: current statusHervé Tilly, Andrew Zelenetz
Leukemia & Lymphoma|February 17, 2012
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone: until what age?Fabrice Jardin, Hervé Tilly
Leukemia & Lymphoma|October 15, 2008
Epidemiology, pathology and treatment of non-follicular indolent lymphomasOla Landgren, Hervé Tilly
Expert Review of Hematology|October 30, 2016
Managing early failures with R-CHOP in patients with diffuse large B-cell lymphomaVincent Camus, Hervé Tilly
The Lancet. Oncology|February 2, 2008
Dose dance in lymphomasBertrand Coiffier, Hervé Tilly
The Lancet. Healthy Longevity|September 14, 2022
Chemotherapy-free treatment in unfit patients aged 75 years and older with DLBCL: toward a new paradigm?Fabrice Jardin, Hervé Tilly
Pageof 26